Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model

Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wihastuti Titin Andri, Heriansyah Teuku, Hanifa Hanifa, Andarini Sri, Sholichah Zuhrotus, Sulfia Yuni Hendrati, Adam Aditya Angela, Refialdinata Jeki, Lutfiana Nurul Cholifah
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2018
Materias:	darapladib atherosclerosis type 2 diabetes mellitus rat model Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/f86c69e1ff364b888452bae779ae9e01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f86c69e1ff364b888452bae779ae9e01
record_format	dspace
spelling	oai:doaj.org-article:f86c69e1ff364b888452bae779ae9e012021-12-02T16:41:13ZDarapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model1336-032910.2478/enr-2018-0008https://doaj.org/article/f86c69e1ff364b888452bae779ae9e012018-04-01T00:00:00Zhttps://doi.org/10.2478/enr-2018-0008https://doaj.org/toc/1336-0329Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulates inflammation mediators, including intra-cellular adhesion molecule-1 (ICAM-1). Darapladib is known as a Lp-PLA2 specific inhibitor. The aim of this study was to reveal the effect of darapladib on the foam cell number, inducible nitric oxide synthase (iNOS), and ICAM-1 expression in aorta at early stages of the atherosclerosis in type 2 diabetes mellitus Sprague-Dawley rat model.Wihastuti Titin AndriHeriansyah TeukuHanifa HanifaAndarini SriSholichah ZuhrotusSulfia Yuni HendratiAdam Aditya AngelaRefialdinata JekiLutfiana Nurul CholifahSciendoarticledarapladibatherosclerosistype 2 diabetes mellitus rat modelDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENEndocrine Regulations, Vol 52, Iss 2, Pp 69-75 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	darapladib atherosclerosis type 2 diabetes mellitus rat model Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	darapladib atherosclerosis type 2 diabetes mellitus rat model Diseases of the endocrine glands. Clinical endocrinology RC648-665 Wihastuti Titin Andri Heriansyah Teuku Hanifa Hanifa Andarini Sri Sholichah Zuhrotus Sulfia Yuni Hendrati Adam Aditya Angela Refialdinata Jeki Lutfiana Nurul Cholifah Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model
description	Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulates inflammation mediators, including intra-cellular adhesion molecule-1 (ICAM-1). Darapladib is known as a Lp-PLA2 specific inhibitor. The aim of this study was to reveal the effect of darapladib on the foam cell number, inducible nitric oxide synthase (iNOS), and ICAM-1 expression in aorta at early stages of the atherosclerosis in type 2 diabetes mellitus Sprague-Dawley rat model.
format	article
author	Wihastuti Titin Andri Heriansyah Teuku Hanifa Hanifa Andarini Sri Sholichah Zuhrotus Sulfia Yuni Hendrati Adam Aditya Angela Refialdinata Jeki Lutfiana Nurul Cholifah
author_facet	Wihastuti Titin Andri Heriansyah Teuku Hanifa Hanifa Andarini Sri Sholichah Zuhrotus Sulfia Yuni Hendrati Adam Aditya Angela Refialdinata Jeki Lutfiana Nurul Cholifah
author_sort	Wihastuti Titin Andri
title	Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model
title_short	Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model
title_full	Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model
title_fullStr	Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model
title_full_unstemmed	Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model
title_sort	darapladib inhibits atherosclerosis development in type 2 diabetes mellitus sprague-dawley rat model
publisher	Sciendo
publishDate	2018
url	https://doaj.org/article/f86c69e1ff364b888452bae779ae9e01
work_keys_str_mv	AT wihastutititinandri darapladibinhibitsatherosclerosisdevelopmentintype2diabetesmellitusspraguedawleyratmodel AT heriansyahteuku darapladibinhibitsatherosclerosisdevelopmentintype2diabetesmellitusspraguedawleyratmodel AT hanifahanifa darapladibinhibitsatherosclerosisdevelopmentintype2diabetesmellitusspraguedawleyratmodel AT andarinisri darapladibinhibitsatherosclerosisdevelopmentintype2diabetesmellitusspraguedawleyratmodel AT sholichahzuhrotus darapladibinhibitsatherosclerosisdevelopmentintype2diabetesmellitusspraguedawleyratmodel AT sulfiayunihendrati darapladibinhibitsatherosclerosisdevelopmentintype2diabetesmellitusspraguedawleyratmodel AT adamadityaangela darapladibinhibitsatherosclerosisdevelopmentintype2diabetesmellitusspraguedawleyratmodel AT refialdinatajeki darapladibinhibitsatherosclerosisdevelopmentintype2diabetesmellitusspraguedawleyratmodel AT lutfiananurulcholifah darapladibinhibitsatherosclerosisdevelopmentintype2diabetesmellitusspraguedawleyratmodel
_version_	1718383610797490176

Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model

Ejemplares similares